KRAS基因突变与分化型甲状腺癌的临床相关性研究

发布时间：2018-04-26 05:27

本文选题：分化型甲状腺癌 + RAS基因　；参考：《昆明医科大学》2017年硕士论文

【摘要】：[目的]检测分化型甲状腺癌中KRAS基因突变率;分析分化型甲状腺癌中KRAS基因突变率与患者年龄、性别、病理类型、被膜浸润、远处转移之间是否存在相关性;判断KRAS基因突变能否作为指导临床治疗及判断预后的指标。[方法]选择2013年01月至2016年12月符合入组的患者44例,选取其存档在昆明医科大学第三附属医院病理科的石蜡包埋组织,每位患者切白片5张,确定含有肿瘤组织;记录所有研究对象的肿瘤大小、病理分型、被膜浸润、远处转移等与之相关的临床病理资料;运用“人类KRAS基因突变检测试剂盒(荧光PCR法)”行KRAS基因突变检测,该试剂盒涵盖KRAS基因2、3、4外显子的11个热点突变,基于扩增阻碍突变系统(Amplification Refractory Mutation System,ARMS)和荧光PCR技术实现样本DNA中KRAS基因的突变检测。[结果]本研究检测了 44例分化型甲状腺癌患者的常见KRAS基因热点突变,均未发现存在KRAS基因热点突变,本课题尚存在不足:样本地域性局限和数量偏少。[结论]分化型甲状腺癌组织中KRAS基因常见热点无突变;分化型甲状腺癌患者的年龄、性别、病理类型、被膜浸润、远处转移与KRAS基因的突变可能无显著相关性,暂不能作为判断分化型甲状腺癌的预后指标。
[Abstract]:[objective] to detect the mutation rate of KRAS gene in differentiated thyroid carcinoma, and to analyze the correlation between the mutation rate of KRAS gene and age, sex, pathological type, membrane infiltration and distant metastasis in differentiated thyroid carcinoma. To determine whether the mutation of KRAS gene can be used as a guideline for clinical treatment and prognosis. [methods] A total of 44 patients from January 2013 to December 2016 were selected and paraffin embedded tissues were selected from the Department of Pathology of the third affiliated Hospital of Kunming Medical University. 5 pieces of white slices were cut from each patient to determine the presence of tumor tissue. The clinical and pathological data of tumor size, pathological type, membrane infiltration and distant metastasis were recorded, and KRAS gene mutation was detected by "human KRAS gene mutation detection kit (fluorescent PCR method)". The kit covers 11 hot spot mutations in exon 2O3O4 of KRAS gene. The mutation detection of KRAS gene in sample DNA is realized based on Amplification Refractory Mutation system and fluorescence PCR technique. [results] in this study, common KRAS gene hot spot mutations were detected in 44 patients with differentiated thyroid carcinoma. None of them found hot spot mutations of KRAS gene. [conclusion] there is no common hot spot mutation of KRAS gene in differentiated thyroid carcinoma, and there may be no significant correlation between age, sex, pathological type, membrane infiltration, distant metastasis and mutation of KRAS gene in differentiated thyroid carcinoma. It can not be used as prognostic index of differentiated thyroid carcinoma for the time being.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R736.1

【参考文献】